Table 8.

Comparison of hypersensitivity reaction and injection-site reaction by ADA status for the primary safety pool (16 weeks) and all risankizumab psoriasis analysis set (52 weeks) for the ADA subset in subjects

	Primary safety pool analysis set [N = 1384] (16 weeks)		All risankizumab doses [N = 1807] ADA subset of all risankizumab psoriasis analysis sets (52 weeks)
	ADA-positive [n = 256]	ADA-negative [n = 1128]	ADA-positive [n = 420]	ADA-negative [n = 1387]
Hypersensitivity reaction (per SMQ) [n (%)]	6 (2.3)	34 (3.0)	32 (7.6)	97 (7.0)
Injection site reaction (per CMQ) [n (%)]	7 (2.7)	15 (1.3)	21 (5.0)	46 (3.3)

Data are expressed as n (%)

ADA antidrug antibodies